Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 101 related to Hibberd: Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus.... (0.14 sec) 

Preemptive ganciclovir therapy to prevent cytomegalovirus disease in …

- annals.org [PDF] 
PL Hibberd, NE Tolkoff-Rubin, D Conti, F … - Annals of internal …, 1995 - Am Coll Physicians
• Objective: To determine why Required Request pol- icies, which mandate that hospitals request
donation from donor-eligible families, have not resulted in in- creased organ procurement. •
Setting: Stratified sample of 23 acute-care general hospitals in two metropolitan areas. • ...
Cited by 166 - Related articles - BL Direct - All 5 versions

Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplants …


DJ Conti, BM Freed, TP Singh, M Gallichio, SA … - Archives of …, 1995 - archsurg.highwire.org
David J. Conti, MD; Brian M. Freed, PhD; T. Paul Singh, MD; Michael Gallichio, MD; Scott A.
Gruber, MD, PhD; Neil Lempert, MD ... Objective: To evaluate the efficacy, safety, and cost of
preemptive ganciclovir therapy in cytomegalovirus (CMV)-seropositive renal transplant ...
Cited by 53 - Related articles - BL Direct - All 4 versions

High-dose acyclovir compared with short-course preemptive ganciclovir therapy to …

- annals.org
N Singh, VL Yu, L Mieles, MM Wagener, RC … - Annals of internal …, 1994 - Am Coll Physicians
Intervention: Patients were stratified by their CMV antibody status and the CMV antibody status
of the donor and were randomly assigned to one of two treatment groups. Surveillance cultures
for CMV (buffy coat and urine) were done every 2 to 4 weeks for 24 weeks in all patients. ...
Cited by 135 - Related articles - All 4 versions

A prospective randomized trial comparing sequential ganciclovir-high dose …


M Martin, R Mañez, P Linden, D Estores, J Torre- … - Transplantation, 1994 - journals.lww.com
780 TRANSPLANTATION Vol. 58, No. 7 prevention of CMV disease in a population of adult patients
undergoing liver transplantation. MATERIALS AND METHODS Randomization and study
protocol. This prospective randomized trial was conducted at the University of Pittsburgh ...
Cited by 78 - Related articles - BL Direct - All 3 versions

Symptomatic cytomegalovirus disease in the cytomegalovirus antibody …


PL Hibberd, NE Tolkoff-Rubin, AB Cosimi, RT … - Transplantation, 1992 - ncbi.nlm.nih.gov
A prospective study to investigate risk factors for CMV disease was conducted in 94 renal transplant
recipients. CMV disease was defined as either unexplained fever for greater than 3 days with
viremia or unexplained fever for greater than 3 days with isolation of CMV from the urine ...
Cited by 178 - Related articles - All 3 versions

Prophylactic oral ganciclovir compared with deferred therapy for control of …


DC Brennan, KA Garlock, GG Singer, MA Schnitzler, BJ … - Transplantation, 1997 - cat.inist.fr
5 Barnes-Jewish Hospital.  6  Health Administration Program, Washington University School
of Medicine. 7 Department of Pediatrics, Washington University School of Medicine. 8 Department
of General Surgery, Transplantation Section, Washington University School of Medicine. t ...
Cited by 122 - Related articles - BL Direct - All 2 versions

Randomised comparison of ganciclovir and high-dose acyclovir for long-term …


DJ Winston, D Wirin, A Shaked, RW Busuttil - The Lancet, 1995 - Elsevier
At the time of transplant, patients were randomised to receive either ganciclovir (6 mg/kg body
weight per day intravenously from postoperative day 1 to day 30, then 6 mg/kg per day Monday
through Friday until day 100) or acyclovir (10 mg/kg intravenously every 8 h from ...
Cited by 179 - Related articles - BL Direct - All 6 versions

Effect of prophylactic ganciclovir on cytomegalovirus infection in renal transplant …


E Rondeau, B Bourgeon, MN Peraldi, P Lang, C … - Nephrology Dialysis …, 1993 - ERA-EDTA
Abstract. Cytomegalovirus (CMV) infection is the most frequent infectious complication observed
in renal transplant recipients and induces a significant morbid- ity in these patients due to CMV
disease itself and to associated renal dysfunction or opportunistic superin- fection. In ...
Cited by 45 - Related articles - BL Direct - All 3 versions

A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart …


TC Merigan, DG Renlund, S Keay, MR … - New England Journal …, 1992 - content.nejm.org
BACKGROUND. Because of the immunosuppression required, heart-transplant recipients frequently
have complications caused by cytomegalovirus (CMV), including pneumonia, esophagitis,
gastritis, and a syndrome of fever, hepatitis, and leukopenia. We undertook a controlled ...
Cited by 261 - Related articles - All 4 versions

Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease …

- asnjournals.org [PDF] 
J Kletzmayr, H Kotzmann, T Popow-Kraupp, J … - Journal of the American …, 1996 - Am Soc Nephrol
Page 1. Journal of the American Society of Nephrology 325 Impact of High-Dose Oral
Acyclovir Prophylaxis on Cytomegalovirus (CMV) Disease in CMV High-Risk Renal
Transplant Recipients1 Josef Kletzmayr, Harald Kolzmann ...
Cited by 54 - Related articles - BL Direct - All 4 versions


Result Page: 

1

2

3

4

5

6

7

8

9

10

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google